<?xml version="1.0" encoding="UTF-8"?>
<p>Preclinical evidence. This herbal medicine has been experimentally proven for anti-viral activity. The commercial extract EPs 7630
 <sup>®</sup> interfered 
 <italic>in vitro</italic> with the replication of different respiratory viruses, including human coronavirus (
 <xref rid="B337" ref-type="bibr">Michaelis et al., 2011</xref>), 
 <italic>Influenza</italic> virus (
 <italic>in vitro</italic> and 
 <italic>in vivo</italic>) (
 <xref rid="B470" ref-type="bibr">Theisen and Muller, 2012</xref>), and 
 <italic>Rhinovirus</italic> isolated from patients with severe asthma (
 <xref rid="B420" ref-type="bibr">Roth et al., 2019</xref>). EPs 7630 was able to stimulate IFN-β 
 <italic>in vitro</italic>, and gallic acid enhanced the expression of iNOS and TNF-α (
 <xref rid="B276" ref-type="bibr">Kolodziej et al., 2003</xref>).
</p>
